Study Applies Luedeking-Piret Model to Forecast Monoclonal Antibody Production Across Multi-Step Manufacturing Processes

A recent study has introduced advancements in forecasting monoclonal antibody (mAb) production using the Luedeking-Piret model. Researchers Wang, Verma, Chiu, and their team have applied this model to address challenges in predicting yield and quality across multi-step manufacturing processes for mAbs. The findings, published in *Communications Engineering* in 2025, aim to improve understanding of the complex production dynamics involved in biopharmaceutical manufacturing.

The study highlights the application of the Luedeking-Piret model as a tool for analyzing and forecasting mAb production outcomes over multiple stages. Monoclonal antibodies are widely used therapeutic agents, but their intricate production processes often require precise engineering solutions to optimize efficiency and ensure product consistency. By leveraging this model, researchers explored its potential to predict key variables such as yield and quality throughout various steps of the manufacturing sequence. This approach may provide insights into improving process control strategies for biopharmaceuticals.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

CDMO Contracts: Analysis Highlights Five Key Areas to Avoid Unexpected Costs and Delays Study Identifies Cellular Network in Immune System That Enables Oral Tolerance to Foods Like Peanuts and Dairy FDA Pilots Quality Management Maturity Program to Encourage Advanced Quality Systems in Pharma Industry Sulfated Yeast Identified as Method to Extract Rare Earth Metals from Electronic Waste

Author

GOAI